Hepsera showing greater choice of therapeutic options

Local studies have shown that GSK's novel nucleotide analogue Hepsera (adefovir dipivoxil; ADV), which was launched in February in Korea, is effective in a broad range of patients with chronic hepatitis B (CHB), including those with lamivudine-resistant HBV, HBV co-infection and decompensated liver function.

Hepsera inhibits reverse transciptase, an essential enzyme in the transcription of H...